insulin
- Generic Name
- insulin
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 363
- Registration Number
- NCT00343980
- Locations
- πΉπ·
Novo Nordisk Investigational Site, Istanbul, Turkey
Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 618
- Registration Number
- NCT00331604
- Locations
- π¬π§
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Human Insulin Inhalation Powder
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1019
- Registration Number
- NCT00330473
- Locations
- πΏπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 596
- Registration Number
- NCT00322257
- Locations
- π¨π¦
Novo Nordisk Investigational Site, Vancouver, Canada
Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.
- Conditions
- Cystic Fibrosis Related Diabetes
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00287456
- Locations
- πΊπΈ
Children's Medical Center of Dallas, Dallas, Texas, United States
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00287066
- Locations
- πΊπΈ
Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States
Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 390
- Registration Number
- NCT00286429
Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes
- Conditions
- GAD Ab Positive Clinically Type 2 Diabetic Patients
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2005-10-04
- Lead Sponsor
- Tokyo Study Group
- Target Recruit Count
- 42
- Registration Number
- NCT00232375
- Locations
- π―π΅
University of Yamanashi, Tamaho, Yamanashi, Japan
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT00232583
- Locations
- πΊπΈ
University of Texas Southwestern, Dallas, Texas, United States
Comparing Two Ways of Controlling Blood Sugar With Insulin in Patients Admitted to the Intensive Care Unit
- Conditions
- Critical IllnessHyperglycemia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 238
- Registration Number
- NCT00166491
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.